Viewing nowHighpyo Tablet (Pioglitazone Hydrochloride)
Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
White Life Sciences Co., Ltd.

MFDS item code 201309032 · Approved 2013.08.28 · Insurance code 625200070
Improvement of glycemic control in type 2 diabetes
This medication is an adjunctive treatment that helps control blood sugar levels in patients with type 2 diabetes. It can be used effectively with diet and exercise to manage blood sugar levels. It can also be used alone and, if necessary, can be combined with other medications such as sulfonylureas, metformin, and insulin. Nutritional counseling, weight loss, and regular exercise are also essential when using this medication. These treatment efforts greatly assist in maintaining the long-term efficacy of the medication, as well as in initial therapy. Therefore, this medication is used to improve blood sugar levels in type 2 diabetes.
This drug should be taken once daily, with or without food. Management of diabetes should be individualized for each patient. The ideal approach is to evaluate the response to treatment by monitoring HbA1c (glycated hemoglobin), which is a more accurate diagnostic measure than FBG (fasting blood glucose). HbA1c reflects blood glucose status over the previous 2~3 months. In clinical practice, this drug should be administered for an appropriate period (at least 3 months) to assess changes in HbA1c, unless glycemic control in the patient with diabetes worsens. Monotherapy: This drug may be initiated at 15mg once daily as monotherapy in patients whose blood glucose is not adequately controlled by diet and exercise. If the initial dose of this drug does not provide an adequate effect, the dose may be increased to 30 mg once daily. Combination therapy should be considered in patients who do not respond adequately to monotherapy. Combination therapy—sulfonylureas: This drug may be administered in combination with a sulfonylurea; the initial dose is 15mg once daily. When this drug is used in combination therapy, the current sulfonylurea may be continued at the same dose and dosing schedule. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. Combination therapy—metformin: This drug may be administered in combination with metformin; the initial dose is 15mg once daily. When this drug is used in combination therapy, the current metformin may be continued at the same dose and dosing schedule. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemic symptoms during combination therapy with this drug. Combination therapy—insulin: This drug may be administered in combination with insulin at a dose of 15mg once daily. The current insulin dose may be continued when starting combination therapy with this drug. However, in patients receiving this drug in combination with insulin, if symptoms of hypoglycemia occur or plasma glucose levels decrease to 100mg/dL or below, the insulin dose may be reduced by 10%~25%. Subsequent dose adjustments should be individualized according to the degree of glycemic control. Maximum recommended dose: For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (see Pharmacokinetics and Drug Metabolism). Treatment with this drug should not be initiated if, at the start of therapy, the patient has clinical evidence of active liver disease or elevated serum transaminase levels (at least 2.5 times the upper limit of normal for ALT) (see Adverse Reactions—Liver; Use in Specific Populations—Hepatic Impairment). Liver enzyme monitoring is recommended in all patients before starting therapy with this drug and periodically thereafter (see Adverse Reactions—Liver). There are no data on administering this drug in combination with other thiazolidinediones.
Children under 18 years of age: Use is not recommended because there is no experience with this drug in this population.
This medication is used in the treatment of diabetes and helps to control blood sugar by acting with insulin. This medication can put a strain on the heart, so patients with heart failure or a history of heart failure should not use it. During treatment, careful monitoring for sudden weight gain, shortness of breath, and swelling in the legs, indicative of heart failure, is necessary. Fluid retention or edema may occur, and if these symptoms worsen, consultation with a physician for medication adjustment is required. Patients with a history of bladder cancer or those with active bladder cancer should not use this medication. If symptoms such as hematuria or urinary problems occur during treatment, notify a physician immediately. Patients with impaired liver function should also undergo regular liver function tests while using this medication. If symptoms suggestive of liver damage arise, consult healthcare personnel immediately. There is a risk of hypoglycemia when taking this medication, so pay special attention to hypoglycemic symptoms, especially when taken with insulin or other hypoglycemic agents. For premenopausal women, ovulation may be stimulated, increasing the likelihood of pregnancy, so using appropriate contraception is essential. Elderly patients or those with reduced kidney function should also take caution while using this medication and adjust the dosage as advised by their doctor. This medication should be taken once daily; if a dose is missed, do not take double the dose the next day. There may be drug interactions, so if you are taking other medications, be sure to inform healthcare personnel. Regular monitoring of blood sugar and liver function tests is important during the treatment period, and if any unusual symptoms appear, seek prompt medical attention.
Congestive heart failure, excessive and rapid weight change, dyspnea, edema, fluid retention, inadequate blood sugar control, upper respiratory infection, headache, sinusitis, myalgia, pharyngitis, abdominal distension, weight gain, hypoglycemia, urinary tract infection, low back pain, dizziness, diarrhea, elevated serum creatine kinase, hypertension, heart failure, limb pain, chest pain, cardiovascular-related death, worsening of congestive heart failure, emergency room visits due to congestive heart failure, progression of congestive heart failure, liver failure, diabetic macular edema with vision reduction, increased blood sugar, anorexia, constipation, upper abdominal pain, chest discomfort, fatigue, weakness, dyspepsia, nausea, itching, chest unease, tremors, chills, gastrointestinal disease, abdominal pain, epigastric discomfort, paresthesia, muscle rigidity, head discomfort, elevated liver enzymes, worsening of liver disease, urticaria, eczema, arthralgia, knee abnormalities, arm weakness, proteinuria, increased serum creatinine, anxiety, insomnia, drowsiness, simplex herpes, blurred vision, orthostatic hypotension, palpitations, stroke, erectile dysfunction, myocardial infarction, heart failure, fractures
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a container that can block light and air, and moisture should be avoided. Additionally, to maintain the efficacy of the drug, it is recommended to store it between 15 to 30 degrees Celsius, especially around 25 degrees Celsius.
White round tablet
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
White Life Sciences Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 33.06mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Hanol Bio Pharma Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Kujoo Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Kyungdong Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.